Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · IEX Real-Time Price · USD
67.88
+0.16 (0.24%)
May 20, 2024, 1:07 PM EDT - Market open
Gilead Sciences Employees
Gilead Sciences had 18,000 employees on December 31, 2023. The number of employees increased by 1,000 or 5.88% compared to the previous year.
Employees
18,000
Change (1Y)
1,000
Growth (1Y)
5.88%
Revenue / Employee
$1,525,000
Profits / Employee
$26,889
Market Cap
84.53B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 18,000 | 1,000 | 5.88% |
Dec 31, 2022 | 17,000 | 2,600 | 18.06% |
Dec 31, 2021 | 14,400 | 800 | 5.88% |
Dec 31, 2020 | 13,600 | 2,600 | 23.64% |
Jan 31, 2019 | 11,000 | 1,000 | 10.00% |
Jan 31, 2018 | 10,000 | 1,000 | 11.11% |
Jan 31, 2017 | 9,000 | 1,000 | 12.50% |
Jan 31, 2016 | 8,000 | 1,000 | 14.29% |
Jan 31, 2015 | 7,000 | 900 | 14.75% |
Jan 31, 2014 | 6,100 | 1,100 | 22.00% |
Jan 31, 2013 | 5,000 | 500 | 11.11% |
Jan 31, 2012 | 4,500 | 500 | 12.50% |
Jan 31, 2011 | 4,000 | 148 | 3.84% |
Jan 31, 2010 | 3,852 | 411 | 11.94% |
Jan 31, 2009 | 3,441 | 462 | 15.51% |
Jan 31, 2008 | 2,979 | 464 | 18.45% |
Jan 31, 2007 | 2,515 | 615 | 32.37% |
Jan 31, 2006 | 1,900 | 246 | 14.87% |
Feb 28, 2005 | 1,654 | 229 | 16.07% |
Feb 27, 2004 | 1,425 | 175 | 14.00% |
Feb 28, 2003 | 1,250 | 250 | 25.00% |
Feb 28, 2002 | 1,000 | 150 | 17.65% |
Feb 28, 2001 | 850 | 90 | 11.84% |
Dec 31, 1999 | 760 | 467 | 159.39% |
Dec 31, 1998 | 293 | 4 | 1.38% |
Dec 31, 1997 | 289 | 41 | 16.53% |
Dec 31, 1996 | 248 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
HCA Healthcare | 310,000 |
CVS Health | 300,000 |
Becton, Dickinson and Company | 73,000 |
Cigna | 72,500 |
GSK | 70,212 |
McKesson | 51,000 |
Bristol-Myers Squibb Company | 34,100 |
Edwards Lifesciences | 19,800 |
GILD News
- 2 days ago - Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis - Business Wire
- 6 days ago - Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy - Business Wire
- 10 days ago - Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program - Business Wire
- 10 days ago - Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program - Business Wire
- 11 days ago - Will Gilead Sciences Stock Recover To Its Pre-Inflation Shock Highs Of Around $75? - Forbes
- 13 days ago - Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024 - Business Wire
- 19 days ago - Gilead Sciences to Present at Upcoming Investor Conferences - Business Wire
- 24 days ago - FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV - Business Wire